Source: International Congress 2017 – Asthma management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Roskos (Gaithersburg, United States of America). Longitudinal modeling of prebronchodilator FEV1 response to benralizumab for patients with severe asthma. 3968

Member's Comments

No comment yet.

Related content which might interest you: Patterns of bronchodilator reversibility of FEV1 in asthma and COPD patients Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Follow-up of patients with severe asthma receiving reslizumab: an FEV1 analysis Source: International Congress 2017 – Asthma management Year: 2017 Comparison of spirometric z-scores with FEV1 percent prediction in predicting exacerbations in elderly COPD patients Source: International Congress 2016 – In-patient and out-patient COPD management Year: 2016 Closing volume predicts the FEV1 response to bronchodilators in patients with COPD Source: Virtual Congress 2020 – Advances in lung function testing Year: 2020 Raised FeNO is associated with lower FEV1 and FEV1/FVC in children with asthma Source: International Congress 2019 – Paediatric asthma: risk factors, biomarkers and the basics Year: 2019 Rate of FEV1 decline by FEV1 percent predicted in UPLIFT® and TIOSPIR® Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Can we use pre-bronchodilator spirometry to define post-bronchodilator airflow obstruction? Source: International Congress 2015 – Epidemiology of respiratory disease Year: 2015 FEV6 and FEV1/FEV6 have higher association with small airway function and oxygen saturation than FVC and FEV1/FVC in patients with asthma. Source: Virtual Congress 2020 – Lung function tests and exhaled biomarkers Year: 2020 Omalizumab significantly improves FEV1 in patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Reducing the decline of FEV1 after a 4-year therapy with montelukast in patients with bronchial asthma Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD Year: 2008 Changes in spirometry (FVC and FEV1) in a closed population of COPD patients using new standarized values for Mexican people Source: Eur Respir J 2003; 22: Suppl. 45, 69s Year: 2003 Maximally attained level of FEV1 and FEV1 decline determine airway hyperresponsiveness in adults Source: Eur Respir J 2003; 22: Suppl. 45, 17s Year: 2003 Baseline FEV1and sputum neutrophils and macrophages predict the decrease in FEV1 after inhaled corticosteroid withdrawal in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 306s Year: 2004 Predictions of post-bronchodilator airflow obstruction by longitudinal asthma and wheeze patterns in middle-age Source: Virtual Congress 2021 – New evidence from longitudinal COPD cohorts and other key studies Year: 2021 Fluctuation analysis of FEV1 in children and adolescents with controlled asthma Source: Virtual Congress 2021 – Best of paediatric physiology and sleep research Year: 2021 Tiotropium: COPD exacerbations and decline in FEV1 Source: Eur Respir J 2001; 18: Suppl. 33, 486s Year: 2001 Comparative study of FEV1/FVC and FEV1/FEV6 to screen COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 511s Year: 2005 Changes in FEV1 and SpO2 in patients with severe and very severe COPD Source: Virtual Congress 2021 – Lung function testing in the management of obstructive diseases Year: 2021 Evaluation of the response of airway obstruction to short-acting inhaled broncodilators with using FIV1 and FEV1 in COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 290s Year: 2005 FEV1 decline in occupational asthma Source: Eur Respir J 2003; 22: Suppl. 45, 488s Year: 2003